Compare Global X Copper Miners ETF (COPX) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Copper Miners ETF vs Cassava Sciences Inc — how do they compare? Global X Copper Miners ETF trades at $85.75 (market cap $7.10B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: Global X Copper Miners ETF is far larger — about 180.2× Cassava Sciences Inc's market cap, and Global X Copper Miners ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Copper Miners ETF for 51 Days and Cassava Sciences Inc for 37 Days on average.
| COPX | FLNA | |
|---|---|---|
Market Cap | $7.10B | $39.40M |
Volume | 2,871,128 | 759,018 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $96.45 | $4.64 |
52-Week Low | $57.43 | $0.68 |
Typical Hold Time | 51 Days | 37 Days |
Enterprise Value | — | -$43.28M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COPX (Global X Copper Miners ETF) trades at $82.22, down 1.63% today amid bearish technical signals. The ETF faces selling pressure with 13 bearish moving average signals versus zero bullish. Copper fundamentals remain strong with prices near all-time highs above $6.85 per pound, driven by AI infrastructure demand and supply constraints. Recent news highlights copper's critical role in electrification and AI infrastructure, though technical indicators suggest near-term weakness.
The long-term copper thesis remains compelling due to structural supply deficits and AI-driven demand, but near-term technical weakness and Federal Reserve policy uncertainty create volatility. Mining equities currently trade at a discount to copper futures, offering potential value. Key risks include global copper surplus projections and macroeconomic sensitivity.
FLNA trades at $0.8136, down 0.26% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates in recent quarters. Recent positive news includes FDA lifting a clinical hold on its epilepsy drug, enabling Phase 2a studies.
The outlook remains high-risk due to persistent negative cash flows and lack of revenue, but analyst consensus is bullish with 67% buy ratings. Key risks include clinical trial execution and funding needs, while the FDA decision provides a potential catalyst for long-term investors focused on biotech turnaround stories.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Global X Copper Miners ETF
COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
